Counterpoint Mutual Funds’s 10x Genomics TXG Stock Holding History

Counterpoint Mutual Funds’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-71,398	Closed	-$835K	–	492
2025 Q3	$835K	Sell	71,398 -6,851	-9%	-$89.3K	0.07%	74
2025 Q2	$906K	Sell	78,249 -274	-0.3%	-$2.5K	0.08%	57
2025 Q1	$686K	Buy	78,523 +26,865	+52%	+$339K	0.1%	121
2024 Q4	$742K	Buy	+51,658	New	+$815K	0.09%	74
2024 Q3	–	Sell	-10,861	Closed	-$211K	–	377
2024 Q2	$211K	Buy	+10,861	New	+$284K	0.05%	176
2023 Q4	–	Sell	-5,177	Closed	-$214K	–	292
2023 Q3	$214K	Buy	5,177 +3,323	+179%	+$173K	0.18%	54
2023 Q2	$104K	Buy	+1,854	New	+$100K	0.1%	229

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Counterpoint Mutual Funds's TXG Position: Q4 2025 in Review

Counterpoint Mutual Funds sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 71,398 shares — an estimated $835K sold.

Counterpoint Mutual Funds first reported a position in TXG in Q2 2023 and held it in 7 quarters. The position peaked at $906K in Q2 2025. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

Counterpoint Mutual Funds reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
Counterpoint Mutual Funds sold 71,398 10x Genomics shares in Q4 2025, an estimated $835K.
Counterpoint Mutual Funds first reported a position in 10x Genomics in Q2 2023 and held it in 7 quarters.
Counterpoint Mutual Funds's 10x Genomics position peaked at $906K in Q2 2025.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Counterpoint Mutual Funds's 13F filing for Q4 2025, filed 12 Feb 2026.